Aardvark Therapeutics, Inc. (AARD)Healthcare | Biotechnology | San Diego, United States | NasdaqGS
6.62 USD
-0.19
(-2.790%) ⇩
(Aug. 27, 2026, 4 p.m.
EDT)
After hours: 6.62 |
Hot Take ↕ | Aug. 22, 2026, 3:16 a.m. EDT
The investment case for Aardvark Therapeutics has collapsed due to a catastrophic combination of clinical failure and regulatory intervention. The company's lead drug candidate faced a cardiac safety issue, triggering an FDA hold and a voluntary pause of its Phase 3 trials, which sent the stock plummeting 32%. Fundamentally, the business is in distress with negative earnings, negative free cash flow, and a deteriorating return on equity. While the balance sheet currently shows low debt, the path to profitability is blocked until the clinical program is resolved. The market has already priced in a severe decline, pushing the stock to its 52-week low, but the uncertainty surrounding the FDA review and the need for a strategic pivot makes this a dangerous speculative vehicle rather than a viable investment. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.338468 |
| AutoETS | 0.347030 |
| AutoARIMA | 0.348585 |
| AutoTheta | 0.372106 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 22.61 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.196 |
| Excess Kurtosis | -1.16 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.905 |
| Market Cap | 144,877,680 |
| Forward P/E | -2.38 |
| Website | https://aardvarktherapeutics.com |
As of Aug. 22, 2026, 3:16 a.m. EDT: Speculators are positioning aggressively for downside protection, evidenced by massive open interest in deep out-of-the-money puts (strikes at $2.50 and $5.00) relative to calls. This 'put skew' suggests a fear of a significant drop rather than a belief in a rally, despite the current price hovering near the 52-week low.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.20240963 |
| Address1 | 4,370 La Jolla Village Drive |
| Address2 | Suite 1050 |
| All Time High | 19.58 |
| All Time Low | 3.35 |
| Ask | 8.62 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 2.3 - Buy |
| Average Daily Volume10 Day | 132,400 |
| Average Daily Volume3 Month | 251,158 |
| Average Volume | 251,158 |
| Average Volume10Days | 132,400 |
| Bid | 4.97 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 3.418 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.62 |
| Current Ratio | 12.629 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 7.085 |
| Day Low | 6.585 |
| Debt To Equity | 0.905 |
| Display Name | Aardvark Therapeutics |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -73,913,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.97 |
| Enterprise Value | 71,684,680 |
| Eps Current Year | -3.1675 |
| Eps Forward | -2.78222 |
| Eps Trailing Twelve Months | -3.22 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.1391 |
| Fifty Day Average Change | 0.4808998 |
| Fifty Day Average Change Percent | 0.07833393 |
| Fifty Two Week Change Percent | -20.240963 |
| Fifty Two Week High | 17.94 |
| Fifty Two Week High Change | -11.320001 |
| Fifty Two Week High Change Percent | -0.63099223 |
| Fifty Two Week Low | 3.35 |
| Fifty Two Week Low Change | 3.27 |
| Fifty Two Week Low Change Percent | 0.9761194 |
| Fifty Two Week Range | 3.35 - 17.94 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,739,457,000,000 |
| Float Shares | 10,938,265 |
| Forward Eps | -2.78222 |
| Forward P E | -2.379395 |
| Free Cashflow | -46,898,876 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 28 |
| Fullday Change | -0.19 |
| Fullday Change Percent | -2.79002 |
| Fullday Price | 6.62 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.16121 |
| Held Percent Institutions | 0.52605 |
| Implied Shares Outstanding | 21,884,846 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,025-02-13 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. |
| Long Name | Aardvark Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 144,877,680 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_614979892 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -69,889,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 149,035,801 |
| Number Of Analyst Opinions | 10 |
| Open | 6.89 |
| Operating Cashflow | -69,408,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 858 225 7696 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 6.62 |
| Post Market Time | 1,787,873,402 |
| Previous Close | 6.81 |
| Price Eps Current Year | -2.0899763 |
| Price Hint | 2 |
| Price To Book | 1.9368051 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.566 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.25 |
| Region | US |
| Regular Market Change | -0.19 |
| Regular Market Change Percent | -2.79002 |
| Regular Market Day High | 7.085 |
| Regular Market Day Low | 6.585 |
| Regular Market Day Range | 6.585 - 7.085 |
| Regular Market Open | 6.89 |
| Regular Market Previous Close | 6.81 |
| Regular Market Price | 6.62 |
| Regular Market Time | 1,787,860,801 |
| Regular Market Volume | 74,111 |
| Return On Assets | -0.4038 |
| Return On Equity | -0.66019994 |
| Sand P52 Week Change | 0.1890428 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 21,884,846 |
| Shares Percent Shares Out | 0.027999999 |
| Shares Short | 611,764 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 651,789 |
| Short Name | Aardvark Therapeutics, Inc. |
| Short Percent Of Float | 0.0418 |
| Short Ratio | 4.22 |
| Source Interval | 15 |
| State | CA |
| Symbol | AARD |
| Target High Price | 45.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 14.5 |
| Target Median Price | 6.5 |
| Total Cash | 73,870,000 |
| Total Cash Per Share | 3.375 |
| Total Debt | 677,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.22 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.109675 |
| Two Hundred Day Average Change | -1.4896755 |
| Two Hundred Day Average Change Percent | -0.18369114 |
| Type Disp | Equity |
| Volume | 74,111 |
| Website | https://aardvarktherapeutics.com |
| Zip | 92,122 |